secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2026-08-13T12:15:11+00:00
Accession:  0001493152-26-037592
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q2 net loss $1.0M; cash $2.2M; merger with Eos on track for Q3 close
------------------------------------------------------------------------------

- Q2 net loss $1.036M ($0.29/share) vs $1.549M loss year ago; R&D expenses <$0.1M.
- Cash and equivalents $2.2M plus $0.7M restricted; going concern assumption within one year.
- Merger with Eos SENOLYTIX expected to close Q3 2026; Form S-4 filed July 9, amended Aug 3.
- G&A expenses down to $1.0M from $1.5M; all clinical development on hold to license/monetize assets.
- iSPERSE patent portfolio ~142 granted patents, 17 US; PUR1900 Phase 3 in India by Cipla.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315226037592/0001493152-26-037592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315226037592/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer